KR102991359B1 - TfR에 결합하는 이중 특이적 항체 - Google Patents
TfR에 결합하는 이중 특이적 항체Info
- Publication number
- KR102991359B1 KR102991359B1 KR1020217019406A KR20217019406A KR102991359B1 KR 102991359 B1 KR102991359 B1 KR 102991359B1 KR 1020217019406 A KR1020217019406 A KR 1020217019406A KR 20217019406 A KR20217019406 A KR 20217019406A KR 102991359 B1 KR102991359 B1 KR 102991359B1
- Authority
- KR
- South Korea
- Prior art keywords
- antibody
- bispecific antibody
- amino acid
- tfr
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPJP-P-2018-248334 | 2018-12-28 | ||
| JP2018248334 | 2018-12-28 | ||
| PCT/JP2019/051594 WO2020138487A1 (ja) | 2018-12-28 | 2019-12-27 | TfRに結合するバイスペシフィック抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210108961A KR20210108961A (ko) | 2021-09-03 |
| KR102991359B1 true KR102991359B1 (ko) | 2026-07-16 |
Family
ID=71125764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217019406A Active KR102991359B1 (ko) | 2018-12-28 | 2019-12-27 | TfR에 결합하는 이중 특이적 항체 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12258413B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3903816A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7506607B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102991359B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113226371B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019413278B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021012569A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3125316A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021007797A (cg-RX-API-DMAC7.html) |
| MY (1) | MY210422A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202106990PA (cg-RX-API-DMAC7.html) |
| TW (2) | TWI873112B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020138487A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113563473A (zh) * | 2020-04-29 | 2021-10-29 | 三生国健药业(上海)股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
| JP7767613B2 (ja) | 2021-11-15 | 2025-11-11 | システィミューン,インコーポレイテッド | 二重特異性抗体-カンプトテシン薬物複合体及びその製薬的使用 |
| KR20250160363A (ko) * | 2023-03-24 | 2025-11-12 | 바이오악틱 에이비 | 인간 트랜스페린 수용체 htfr1의 프로테아제-유사 도메인에 결합하는 항체 |
| KR20260044219A (ko) | 2023-07-21 | 2026-04-01 | 매로우 테라퓨틱스, 인크. | 조혈 세포 표적화 접합체 및 관련 방법 |
| IL327952A (en) * | 2023-10-26 | 2026-06-01 | Biogen Ma Inc | Anti-transferrin receptor antibodies and uses thereof |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US570561A (en) | 1896-11-03 | S peters co | ||
| US2808035A (en) | 1953-04-23 | 1957-10-01 | Riley Stoker Corp | Burning wet materials |
| JPS5623587A (en) | 1979-08-03 | 1981-03-05 | Mitsuwa Seiki Co Ltd | Vane type compressor |
| JPS58110600A (ja) | 1981-12-25 | 1983-07-01 | Kyowa Hakko Kogyo Co Ltd | ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド |
| WO1985003934A1 (fr) | 1984-03-06 | 1985-09-12 | Takeda Chemical Industries, Ltd. | Proteine modifiee chimiquement et son procede de preparation |
| JPS60221091A (ja) | 1983-12-21 | 1985-11-05 | Kyowa Hakko Kogyo Co Ltd | 新規プロモ−タ− |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| JP2564268B2 (ja) | 1985-08-28 | 1996-12-18 | 協和醗酵工業株式会社 | 融合抗原ポリペプチド |
| ZA872705B (en) | 1986-04-22 | 1987-10-05 | Immunex Corporation | Human g-csf protein expression |
| JP2958019B2 (ja) | 1988-05-06 | 1999-10-06 | 住友製薬株式会社 | ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法 |
| JP2928287B2 (ja) | 1988-09-29 | 1999-08-03 | 協和醗酵工業株式会社 | 新規ポリペプチド |
| JPH02257891A (ja) | 1989-03-31 | 1990-10-18 | Kyowa Hakko Kogyo Co Ltd | 組換え動物細胞による蛋白質の製造 |
| JPH0322979A (ja) | 1989-06-19 | 1991-01-31 | Kyowa Hakko Kogyo Co Ltd | 新規プラスミノーゲン活性化因子 |
| JP3131322B2 (ja) | 1991-12-17 | 2001-01-31 | 協和醗酵工業株式会社 | 新規α2→3シアリルトランスフェラーゼ |
| US6042828A (en) | 1992-09-07 | 2000-03-28 | Kyowa Hakko Kogyo Co., Ltd. | Humanized antibodies to ganglioside GM2 |
| WO1994023021A1 (fr) | 1993-03-29 | 1994-10-13 | Kyowa Hakko Kogyo Co., Ltd. | α-1,3-FUCOSYLTRANSFERASE |
| US5705614A (en) | 1993-04-09 | 1998-01-06 | Chiron Corporation | Methods of producing antigen forks |
| CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
| ES2233974T3 (es) | 1995-09-11 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana. |
| US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| PT2857516T (pt) | 2000-04-11 | 2017-08-28 | Genentech Inc | Anticorpos multivalentes e utilizações dos mesmos |
| PT2990420T (pt) * | 2000-05-26 | 2017-03-16 | Immunex Corp | Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos |
| PE20020132A1 (es) | 2000-06-29 | 2002-03-04 | Abbott Lab | Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos |
| CN103333860B (zh) | 2000-10-06 | 2015-07-08 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
| EP1369431A4 (en) | 2001-10-15 | 2005-01-12 | Kirin Brewery | ANTI-HLA-DR ANTIBODIES |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| JPWO2005035586A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | 融合蛋白質組成物 |
| JP4958555B2 (ja) | 2004-09-22 | 2012-06-20 | 協和発酵キリン株式会社 | 安定化されたヒトIgG4抗体 |
| US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP2281845B1 (en) | 2008-04-25 | 2020-09-02 | Kyowa Kirin Co., Ltd. | Stable polyvalent antibody |
| US9221902B2 (en) * | 2008-11-07 | 2015-12-29 | Fabrus, Inc. | Combinatorial antibody libraries and uses thereof |
| CN102459344A (zh) * | 2009-05-15 | 2012-05-16 | 中外制药株式会社 | 抗axl抗体 |
| CN102803484A (zh) | 2009-06-11 | 2012-11-28 | 大学共同利用机关法人情报·系统研究机构 | 生产蛋白质的方法 |
| WO2011116387A1 (en) | 2010-03-19 | 2011-09-22 | Tetragenetics, Inc. | Production of aglycosylated monoclonal antibodies in ciliates |
| CN103443125B (zh) * | 2010-11-30 | 2019-05-03 | 霍夫曼-拉罗奇有限公司 | 低亲和力血脑屏障受体抗体及其用途 |
| US9206257B2 (en) | 2011-04-19 | 2015-12-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for glypican-3 and use thereof |
| US9598496B2 (en) | 2011-05-09 | 2017-03-21 | Perseus Proteomics Inc. | Antibody capable of specifically recognizing transferrin receptor |
| US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
| US9527927B2 (en) | 2011-12-20 | 2016-12-27 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
| SG10201704846VA (en) | 2012-03-14 | 2017-07-28 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| WO2013177062A2 (en) | 2012-05-21 | 2013-11-28 | Genentech, Inc. | Methods for improving safety of blood-brain barrier transport |
| SG11201509566RA (en) | 2013-05-20 | 2015-12-30 | Genentech Inc | Anti-transferrin receptor antibodies and methods of use |
| US9388243B2 (en) | 2013-05-29 | 2016-07-12 | Samsung Electronics Co., Ltd. | Method of target membrane protein depletion |
| TWI702316B (zh) * | 2013-12-04 | 2020-08-21 | 日商中外製藥股份有限公司 | 因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫 |
| AU2015242752A1 (en) * | 2014-04-04 | 2016-10-20 | Kyowa Hakko Kirin Co., Ltd. | Anti-death receptor 3 (DR3) antagonistic antibodies with reduced agonistic activity |
| JP6779876B2 (ja) * | 2014-11-19 | 2020-11-04 | ジェネンテック, インコーポレイテッド | 抗トランスフェリン受容体抗体及びその使用方法 |
| EP3221361B1 (en) * | 2014-11-19 | 2021-04-21 | Genentech, Inc. | Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use |
| US20180016346A1 (en) * | 2015-01-08 | 2018-01-18 | Kyowa Hakko Kirin Co., Ltd | Bispecific antibody binding to trailr2 and psma |
| AU2016282334B2 (en) * | 2015-06-24 | 2022-07-21 | F. Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies with tailored affinity |
| TWI726897B (zh) * | 2015-07-15 | 2021-05-11 | 日商協和麒麟股份有限公司 | 與人類crth2特異性結合之抗體 |
| US20190161535A1 (en) * | 2016-05-09 | 2019-05-30 | Annexon, Inc. | Compositions and methods for treating spinal muscular atrophy |
| KR102156626B1 (ko) | 2018-07-16 | 2020-09-17 | 주식회사 셀바스에이아이 | 운동 처방 정보를 제공하는 서버 및 컴퓨터 프로그램 |
-
2019
- 2019-12-27 KR KR1020217019406A patent/KR102991359B1/ko active Active
- 2019-12-27 MX MX2021007797A patent/MX2021007797A/es unknown
- 2019-12-27 CA CA3125316A patent/CA3125316A1/en active Pending
- 2019-12-27 TW TW108148133A patent/TWI873112B/zh active
- 2019-12-27 CN CN201980086662.6A patent/CN113226371B/zh active Active
- 2019-12-27 EP EP19901837.5A patent/EP3903816A4/en active Pending
- 2019-12-27 MY MYPI2021003612A patent/MY210422A/en unknown
- 2019-12-27 SG SG11202106990PA patent/SG11202106990PA/en unknown
- 2019-12-27 US US17/418,447 patent/US12258413B2/en active Active
- 2019-12-27 TW TW114101537A patent/TWI907249B/zh active
- 2019-12-27 BR BR112021012569-8A patent/BR112021012569A2/pt unknown
- 2019-12-27 JP JP2020562545A patent/JP7506607B2/ja active Active
- 2019-12-27 AU AU2019413278A patent/AU2019413278B2/en active Active
- 2019-12-27 WO PCT/JP2019/051594 patent/WO2020138487A1/ja not_active Ceased
-
2024
- 2024-06-14 JP JP2024096802A patent/JP2024119984A/ja active Pending
-
2025
- 2025-02-19 US US19/057,265 patent/US20250250352A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020138487A1 (ja) | 2020-07-02 |
| EP3903816A1 (en) | 2021-11-03 |
| EP3903816A4 (en) | 2022-09-07 |
| AU2019413278A1 (en) | 2021-07-15 |
| MY210422A (en) | 2025-09-22 |
| NZ777568A (en) | 2025-05-02 |
| JPWO2020138487A1 (ja) | 2021-11-11 |
| US20250250352A1 (en) | 2025-08-07 |
| TWI907249B (zh) | 2025-12-01 |
| SG11202106990PA (en) | 2021-07-29 |
| MX2021007797A (es) | 2021-10-26 |
| TWI873112B (zh) | 2025-02-21 |
| CA3125316A1 (en) | 2020-07-02 |
| TW202039581A (zh) | 2020-11-01 |
| JP7506607B2 (ja) | 2024-06-26 |
| KR20210108961A (ko) | 2021-09-03 |
| BR112021012569A2 (pt) | 2021-09-14 |
| US20220017635A1 (en) | 2022-01-20 |
| CN113226371B (zh) | 2025-05-30 |
| JP2024119984A (ja) | 2024-09-03 |
| US12258413B2 (en) | 2025-03-25 |
| CN113226371A (zh) | 2021-08-06 |
| AU2019413278B2 (en) | 2026-04-09 |
| TW202517296A (zh) | 2025-05-01 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PA0102 | Application to register extension of term of patent right following delayed registration |
St.27 status event code: A-4-4-G10-G15-tad-PA0102 Protection beyond ip right term event data comment text: Claim Total Quantity : 0, Period Limitation Text : 8 |